Applied Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Applied Therapeutics CEO'su Les Funtleyder, Nov2023 tarihinde atandı, in görev süresi 1.08 yıldır. şirketin hisselerinin 0.078% doğrudan sahiptir ve bu hisselerin değeri $ 76.99K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1 yıl ve 6.7 yıldır.

Anahtar bilgiler

Les Funtleyder

İcra Kurulu Başkanı

US$675.2k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.1yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	1yrs
Yönetim Kurulu ortalama görev süresi	6.7yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Nov 15

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Sep 18

Applied Therapeutics: Pushing Towards FDA Approval

Sep 04

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Aug 01

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

May 28

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24

Applied Therapeutics EPS misses by $0.21

Nov 12

CEO

Les Funtleyder (54 yo)

1.1yrs

Görev süresi

US$675,150

Tazminat

Mr. Les D. Funtleyder is the Interim Chief Executive Officer of Applied Therapeutics, Inc. since December 20, 2024. He is Independent Director of Reviva Pharmaceuticals Holdings, Inc. since December 8, 202...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Les Funtleyder	Interm CEO	1.1yrs	US$675.15k	0.078% $ 77.0k
Shoshana Shendelman	Founder	no data	US$9.49m	3.91% $ 3.9m
Riccardo Perfetti	Chief Medical Officer	6.3yrs	US$3.04m	0.14% $ 143.4k
John Johnson	Executive Chairman	no data	Veri yok	Veri yok
Constantine Chinoporos	COO & Chief Business Officer	less than a year	Veri yok	Veri yok
Catherine Thorpe	Chief Accounting Officer	1.5yrs	Veri yok	Veri yok
Corwin Hooks	Chief Commercial Officer	less than a year	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: APLT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Les Funtleyder	Interm CEO	8.5yrs	US$675.15k	0.078% $ 77.0k
Shoshana Shendelman	Founder	8.9yrs	US$9.49m	3.91% $ 3.9m
John Johnson	Executive Chairman	no data	Veri yok	Veri yok
Jay Skyler	Independent Director	5.7yrs	US$92.53k	0.017% $ 17.0k
Lawrence Steinman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Teena Lerner	Lead Independent Director	7.8yrs	US$88.78k	0.052% $ 51.5k
Stacy Kanter	Independent Director	5.6yrs	US$94.40k	0.054% $ 53.6k
Gregg Stone	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Donald Landry	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Donald D'Amico	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Roy Freeman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Roxana Mehran	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

6.7yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: APLT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/24 01:14
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Applied Therapeutics, Inc. 12 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Brian Skorney	Baird
Carter Gould	Barclays
Catherine Seifert	CFRA Equity Research

Applied Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Chair of the Board of Directors recently sold US$1.7m worth of stock

Independent Director recently bought US$65k worth of stock

Recent updates

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Applied Therapeutics, Inc Announces Chief Executive Officer Changes

Robbins Geller Rudman & Dowd LLP Announces That Applied Therapeutics, Inc. Investors with Substantial Losses Has Opportunity to Lead the Applied Therapeutics Class Action Lawsuit

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

Applied Therapeutics: Pushing Towards FDA Approval

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Consensus revenue estimates decrease by 38%

Consensus revenue estimates decrease by 26%

Forecast to breakeven in 2026

Applied Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Applied Therapeutics, Inc. Announces Management Changes

Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

Chair of the Board of Directors recently sold US$1.7m worth of stock

New major risk - Revenue and earnings growth

Applied Therapeutics, Inc. announced that it expects to receive $99.997998 million in funding from a group of investors

Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Applied Therapeutics, Inc. Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Independent Director recently bought US$65k worth of stock

Applied Therapeutics, Inc. Appoints Les Funtleyder as Chief Financial Officer, Effective November 20, 2023

Consensus EPS estimates fall by 36%

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

New major risk - Shareholder dilution

Consensus EPS estimates fall by 13%

Consensus revenue estimates fall by 27%

New major risk - Financial position

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$13.63

Price target decreased to US$28.80

Applied Therapeutics, Inc. Announces Executive Changes

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Price target increased to US$39.20

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Applied Therapeutics, Inc Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Price target decreased to US$34.40

Price target increased to US$49.40

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Chair of the Board of Directors recently bought US$145k worth of stock

Chief Medical Officer notifies of intention to sell stock

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Chief Medical Officer exercised options and sold US$714k worth of stock

Chief Medical Officer exercised options and sold US$97k worth of stock

Price target decreased to US$44.50

Applied Therapeutics Grants Fast Track Designation by FDA for AT-007 for Galactosemia

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

CFO & Head of Business Development recently sold US$108k worth of stock